Ironwood Pharmaceuticals (NASDAQ:IRWD) Hits New 12-Month High at $14.30

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWDGet Free Report)’s stock price reached a new 52-week high during trading on Monday . The company traded as high as $14.30 and last traded at $14.30, with a volume of 806 shares trading hands. The stock had previously closed at $13.39.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on IRWD. StockNews.com began coverage on Ironwood Pharmaceuticals in a research report on Thursday, October 5th. They set a “hold” rating on the stock. Craig Hallum began coverage on Ironwood Pharmaceuticals in a research report on Wednesday, January 17th. They set a “buy” rating and a $21.00 target price on the stock. Jefferies Financial Group began coverage on Ironwood Pharmaceuticals in a research report on Thursday, November 9th. They set a “buy” rating and a $21.00 target price on the stock. Finally, Wells Fargo & Company initiated coverage on Ironwood Pharmaceuticals in a research report on Thursday, December 14th. They set an “overweight” rating and a $20.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.60.

View Our Latest Stock Report on Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Trading Up 0.3 %

The company has a market capitalization of $2.15 billion, a price-to-earnings ratio of -2.22 and a beta of 0.75. The company has a fifty day moving average of $11.50 and a 200-day moving average of $10.26.

Ironwood Pharmaceuticals (NASDAQ:IRWDGet Free Report) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.05). Ironwood Pharmaceuticals had a positive return on equity of 112.29% and a negative net margin of 220.24%. The firm had revenue of $113.74 million during the quarter, compared to analyst estimates of $112.90 million. During the same quarter in the previous year, the firm posted $0.28 earnings per share. The company’s quarterly revenue was up 4.7% on a year-over-year basis. As a group, equities research analysts expect that Ironwood Pharmaceuticals, Inc. will post 1.07 EPS for the current year.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. KBC Group NV acquired a new position in shares of Ironwood Pharmaceuticals during the 2nd quarter valued at about $118,000. Los Angeles Capital Management LLC boosted its position in shares of Ironwood Pharmaceuticals by 11.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 214,661 shares of the biotechnology company’s stock valued at $2,284,000 after acquiring an additional 22,105 shares during the last quarter. Profund Advisors LLC boosted its position in shares of Ironwood Pharmaceuticals by 12.7% during the 2nd quarter. Profund Advisors LLC now owns 136,980 shares of the biotechnology company’s stock valued at $1,457,000 after acquiring an additional 15,485 shares during the last quarter. Barclays PLC lifted its stake in shares of Ironwood Pharmaceuticals by 28.8% in the 2nd quarter. Barclays PLC now owns 454,798 shares of the biotechnology company’s stock valued at $4,839,000 after purchasing an additional 101,785 shares during the last quarter. Finally, Exchange Traded Concepts LLC lifted its stake in shares of Ironwood Pharmaceuticals by 46.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 235,690 shares of the biotechnology company’s stock valued at $2,270,000 after purchasing an additional 74,758 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

(Get Free Report)

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries.

Featured Articles

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.